Archive for the ‘Marshall Edwards Inc’ Category

Marshall Edwards Inc

April 30th, 2012 | Posted in 2012, Marshall Edwards Inc

Marshall Edwards Inc. – San Diego:  Announced that its lead drug candidate for use in treating cancer, ME-143, has been issue a patent by the U.S. Patent and Trademark Office.

Marshall Edwards Inc

September 22nd, 2011 | Posted in 2011, Marshall Edwards Inc

Marshall Edwards Inc. – San Diego:  Is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism.  The company announced that the first patient was dosed in the company’s Phase 1 clinical trial of its lead drug candidate ME-143 in patients with refactory solid tumors. The trial is conducted in collaboration […]

Marshall Edwards Inc

September 15th, 2011 | Posted in Marshall Edwards Inc

Marshall Edwards Inc. – San Diego:  Is an oncology company that is focused on the clinical development of a novel therapeutics targeting cancer metabolish.  The company announced that its Investigational New Drug (IND) application for ME-143 has been approved by the U.S. Food and Drug Administration. The company plans to initiate Phase 1 clinical trial […]

Marshall Edwards Inc

September 9th, 2010 | Posted in Marshall Edwards Inc

Marshall Edwards Inc., San Diego, is an oncology company that is focused on the clinical development of novel anti-cancer therapeutics.  Marshall Edwards Inc. has reached an Agreement to acquire Novogen Limited’s isoflavone-related intellectual property portfolio.  Daniel Gold is President and CEO of Marshall Edwards Inc.